The CEO of Novartis on Growing After a Patent Cliff  

Oleh:

Jimenez, Joseph

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Harvard Business Review bisa di lihat di link (http://web.b.ebscohost.com/ehost/command/detail?sid=f227f0b4-7315-44a4-a7f7-a7cd8cbad80b%40sessionmgr114&vid=12&hid=105&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=bth&jid=HBR) vol. 90 no. 12 (Dec. 2012), page 39-42.
Topik: Pharmaceutical Company; Drugs; Business Strategy

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: HH10.46 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

When blockbuster drugs give way to generics, pharmaceutical companies like Novartis must find new ways to grow. For more than a decade, the top-selling Novartis product has been a drug called Diovan. It’s an anti-hypertensive, which means that it treats high blood pressure, and patients who need it take the medicine every day. Scientists inside our company spent many years developing Diovan, and it has been tested on thousands of patients in clinical trials. Altogether Novartis spent well over a billion dollars on development and received a patent to sell Diovan exclusively for 14 years. When I joined Novartis, in 2007, our entire pharmaceuticals division had revenue of about $24 billion, and Diovan accounted for $5 billion of that.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali